The best scenario is that rosiglitazone may be neutral and the worst case is that it increases heart failure and cardiovascular events, said Dr. Robert Scott III, associate professor of internal medicine at Texas A & M Health Science Center College of Medicine and senior staff cardiologist, Scott & White in Temple. All studies to date suggest that it might be safer to choose pioglitazone.A higher risk of Avandia no biological sense. Previous research has shown that the drug increases the LDL or bad cholesterol and may also have negative effects associated with the genetic enzyme involved in plaque rupture in the inner lining of blood vessels.
The author of the report is David Graham, a researcher at the Center for Drug Evaluation and Research, FDA. Graham was one of the first government scientists to highlight the dangers of heart rofecoxib (Vioxx), a COX-2 inhibitor painkiller that was withdrawn from the market in 2004. Avandia his team’s study was funded by various offices and agencies, including FDA.
If these new results will be convincing to the committee remains to be seen.
Amidst all this controversy, a 2004 legal settlement forced GlaxoSmithKline, the manufacturer of Avandia, to make all clinical trial results public.
Both Avandia and Actos, made by Takeda Pharmaceuticals, belong to the class of drugs called thiazolidinediones.
According to data collected from several large clinical studies, the diabetes medication Avandia increases the chances of having a heart attack, reinforcing the view that the drug’s risks may outweigh the benefits for people with type 2 diabetes.
Both documents are published online in advance of a Food and Drug Administration advisory committee that is set to convene in July to recommend the fate of the best-selling drug.
Avandia is not, however, show an increased risk of death from cardiovascular disease, said the authors of a meta-analysis in the June 28 issue of Archives of Internal Medicine online.
Suggestions of heart problems the first time in 2007. Since then, many other studies have found an increased risk of heart attack, although some research is actually an advantage.
According to background information in the study, Nissen has received payments from various pharmaceutical companies, but all the money contributed to charity.
SOURCES: Steven E. Nissen, MD, Chairman, Department of Cardiovascular Medicine, Cleveland Clinic, Robert Scott III, MD, Ph.D., Associate Professor, Internal Medicine, Texas A & M Health Science Center College of Medicine and senior cardiologist, Scott & White, Temple Kirk Garratt, MD, clinical director, interventional cardiovascular research, Lenox Hill Hospital in New York, June 28, 2010, Archives of Internal Medicine, online June 28, 2010, Journal of the American Medical Association, in line
A second study, appearing in a publication partner, the number of the line June 28 in the Journal of the American Medical Association (JAMA), found that patients older than 65 years, taking rosiglitazone (Avandia) carried a higher risk of heart failure, stroke and death from all causes compared to a similar drug known as pioglitazone (Actos).
Nissen, with the American Diabetes Association and European Association for the Study of Diabetes, does not believe Avandia should remain on the market.
In February of this year, the FDA said it was still examining documents relating to Avandia and wasn t ready to make decisions about the drug.
The authors of the JAMA study scoured the pharmacy records of nearly 227,600 Medicare patients participating in Medicare Part D drug. They found that Avandia increased the risk of heart attack, stroke or death from any cause compared to Actos.
I think it’s scientifically convincing enough to have two of these studies before the FDA advisory committee meeting, but advisory committees have been very reluctant to take drugs from the market, said Dr. Steve Nissen, lead author of the analysis of documents d ‘ Archive and chairman of the department of cardiovascular medicine at the Cleveland Clinic. And it is very difficult for physicians who are accustomed to using drugs to say they did the wrong thing. Clinical inertia is a very big problem in medicine.
Avandia was approved by the FDA in 1999 for the treatment of hyperglycemia in patients with type 2 diabetes.
Combining data from all these studies showed that Avandia increased the risk of heart attack by 28 percent to 39 percent, but not the risk of cardiovascular mortality.
A randomized controlled trial, sent by the FDA, is led by GlaxoSmithKline and is currently recruiting patients.
The analysis revealed that, compared to those taking Actos, the risk of heart failure was 25 percent higher with Avandia and the risk of stroke was 27 percent higher and the risk of death from any cause is was 14 percent more.
This group of drugs is different from most of the drugs we use. They are actually modify gene expression, says Garratt. Every time you go in and play with the expression of the gene, you must be prepared to find unexpected results.
Nissen and colleagues looked for these results and two other databases, ultimately identifying 56 randomized controlled trials involving a total of over 35 500 patients.
In 2007, an FDA advisory committee said Avandia does increase the risk of heart attacks, but short of recommending pulling the shelves of pharmacies.
Since cardiovascular disease is already the leading cause of death for people with type 2 diabetes, the increased risk is significant, the authors said.
Dr. Kirk Garratt, clinical director of interventional cardiovascular research at Lenox Hill Hospital in New York, admitted that he doesn t good for rosiglitazone, but also said the FDA for the most part out of a sort of warning. I doubt that the risk associated with this drug will be felt to be sufficiently bad to justify the removal of the market.